Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025
FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, is proud to announce it advanced discussions with key US Government agencies through its participation in the 2025 Military Health System Research Symposium (MHSRS), held August 4-7, 2025, in Kissimmee, Florida. The MHSRS is the Department of Defense’s premier scientific meeting that brings together military, academic, and industry experts to discuss medical research and innovation
Related Questions
How will the advancement of Entolimod discussions affect Tivic Health's revenue projections?
What potential contracts or funding could arise from the Department of Defense partnership?
Will the collaboration with US Government agencies accelerate regulatory approvals for Entolimod?
How does this development compare to competitors' radiation countermeasure pipelines?
What is the expected timeline for Entolimod to enter clinical trials or market?
Could this partnership lead to additional licensing or co-development opportunities for Tivic Health?
How might the market react to Tivic Health's involvement in a high-profile defense research symposium?
What are the risks if the discussions with government agencies do not result in tangible agreements?
Will this news impact Tivic Health's cash burn rate or capital requirements?
How could this partnership influence Tivic Health's valuation multiples relative to industry peers?